Litcius/Paper detail

Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial

Jeanne E. Poole, Jeanne E. Poole, Tristram D. Bahnson, Kristi H. Monahan, George Johnson, Hoss Rostami, A Silverstein, Hussein R. Al‐Khalidi, Yves Rosenberg, Daniel B. Mark, Kerry L. Lee, Douglas L. Packer, Jeanne E. Poole, Jeanne E. Poole, Nazem Akoum, Pierre S. Aoukar, Ulrika Birgersdotter‐Green, Joseph Blatt, Yong‐Mei Cha, Mina K. Chung, Marye J. Gleva, Taya V. Glotzer, Charles Henrickson, Jack Kron, Vikas Kuriachan, Siva K. Mulpuru, Peter A. Noseworthy, Kris Patton, Jordan M. Prutkin, Ravi Ranjan, Robert W. Rho, Andrea M. Russo, Eric C. Stecker, Wendy S. Tzou, Laura Vitali Serdoz, Mauri Wilson

2020Journal of the American College of Cardiology261 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAtrial fibrillationHazard ratioCatheter ablationInternal medicineCardiologyAsymptomaticConfidence intervalStroke (engine)Randomized controlled trialAblationCardiac AblationSurgeryMechanical engineeringEngineeringAtrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiovascular Disease and Adiposity
Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial | Litcius